Morgan Stanley Assumes ProKidney at Equal-Weight, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Judah Frommer has initiated coverage on ProKidney (NASDAQ:PROK) with an Equal-Weight rating and set a price target of $3.

March 07, 2024 | 9:22 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has initiated coverage on ProKidney with an Equal-Weight rating and a price target of $3.
The initiation of coverage by a major financial institution like Morgan Stanley generally brings increased attention to a stock. An Equal-Weight rating suggests a neutral outlook, indicating that the analyst believes the stock will perform in line with the market or its sector. The set price target provides a specific value expectation, which can influence investor sentiment and stock price movement. However, the neutral stance means the immediate impact on the stock price might be limited.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100